hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma-Reference-Cited by-同舟云学术

hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma

Published:2010-08-10 Issue:6 Volume:103 Page:812-819
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Cocco E,Hu Z,Richter C E,Bellone S,Casagrande F,Bellone M,Todeschini P,Krikun G,Silasi D-A,Azodi M,Schwartz P E,Rutherford T J,Buza N,Pecorelli S,Lockwood C J,Santin A D

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6605760.pdf

Reference43 articles.

1. Abe K, Shoji M, Chen J, Bierhaus A, Danave I, Micko C, Casper K, Dillehay DL, Nawroth PP, Rickles FR (1999) Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA 96: 8663–8668

2. Abulafia O, Triest WE, Sherer DM (1999) Angiogenesis in malignancies of the female genital tract. Gynecol Oncol 72: 220–231

3. Alessi P, Ebbinghaus C, Neri D (2004) Molecular targeting of angiogenesis. Biochim Biophys Acta 4 (1654): 39–49

4. Bohkman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15: 10–17

5. Bristow RE (1999) Endometrial cancer. Curr Opin Oncol 11: 388–393

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrating antibody drug conjugates in the management of gynecologic cancers;International Journal of Gynecologic Cancer;2023-03

2. A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer;Frontiers in Pharmacology;2022-12-22

3. The roles and clinical applications of interleukins in endometrial carcinoma;Frontiers in Oncology;2022-11-30

4. Tissue Factor and Extracellular Vesicles: Activation of Coagulation and Impact on Survival in Cancer;Cancers;2021-07-30

5. Tisotumab Vedotin in Cervical Cancer: Current Status and Future Perspectives;Oncology & Haematology;2021